← All trials
NCT06522945
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2024
- Primary completion
- Dec 31, 2024
- Completion date
- Mar 31, 2025
- First posted
- Jul 26, 2024
- Last posted
- Jul 26, 2024
- Enrollment
- 48
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,LtdLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.